Ramm Pharma (RAMM) AI Stock Analysis

• Market Cap: C$2.39M
• Dividend Yield: N/A
• Average Volume (3M): 118.29K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.15
• Revenue Growth: -15.51%
• EPS Growth: -49.26%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 119,389,320
• 10 Day Avg. Volume: 262,784
• 30 Day Avg. Volume: 118,288
• PEG Ratio: <0.01
• Price to Book (P/B): 0.31
• Price to Sales (P/S): 0.53
• P/FCF Ratio: -1.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.02 ▼(-66.67% Downside)
• Action: Reiterated Date: 04/08/26
• Date: Action: Reiterated 04/08/26

The score is held down primarily by very weak financial performance (sharp TTM revenue decline, severe losses, and ongoing cash burn) despite low leverage. Technicals also lean bearish (below key moving averages and negative MACD), while valuation metrics offer limited support because the company is loss-making (negative P/E) and no dividend yield is provided.

Positive Factors

Low Leverage

A near-zero debt load materially reduces interest burden and refinancing risk, giving management time and flexibility to execute restructuring or strategic options. Over a 2–6 month horizon this conservatism preserves optionality to raise capital or pursue partnerships without immediate solvency pressure.

Negative Factors

Sharply Declining Revenue

Sustained and material revenue contraction undermines scale economics and makes fixed-cost recovery harder. Over a multi-month horizon, falling top-line reduces ability to invest in R&D or commercialization, exacerbates margin pressure, and increases reliance on external funding to sustain operations.

Ramm Pharma Business Overview & Revenue Model

Company Description

RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. ...

Read more

RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. ...

How the Company Makes Money

null...

Ramm Pharma Financial Statement Overview

Breakdown	Jan 2026	Jan 2025	Jan 2024	Jan 2023	Jan 2022
Income Statement
Total Revenue	3.36M	4.34M	5.07M	3.90M	4.12M
Gross Profit	373.93K	1.76M	381.82K	530.50K	-7.64K
EBITDA	-3.78M	-15.23M	-6.30M	-19.91M	-6.36M
Net Income	-8.91M	-16.50M	-7.72M	-20.96M	-7.11M
Balance Sheet
Total Assets	9.27M	16.75M	32.30M	39.31M	59.71M
Cash, Cash Equivalents and Short-Term Investments	803.88K	814.04K	5.12M	9.77M	17.16M
Total Debt	80.39K	188.31K	405.14K	683.70K	32.16K
Total Liabilities	3.57M	3.11M	2.84M	3.72M	3.32M
Stockholders Equity	5.70M	13.63M	29.46M	35.59M	56.39M
Cash Flow
Free Cash Flow	-1.06M	-4.05M	-4.45M	-6.08M	-4.25M
Operating Cash Flow	-1.06M	-4.00M	-4.34M	-5.91M	-3.82M
Investing Cash Flow	1.22M	-47.43K	126.58K	-1.15M	-6.83M
Financing Cash Flow	-154.07K	-258.23K	-409.97K	-353.77K	-190.33K

Ramm Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 30.24 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RAMM.

Ramm Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INNO	51 Neutral	C$29.96M	-19.43	-71.80%	―	-3.94%	-17.62%
ATLE	50 Neutral	C$59.88M	-2.97	-19.76%	―	26.91%	81.01%
LABS	49 Neutral	C$27.35M	-3.31	-19.10%	―	18.06%	34.58%
AVCN	46 Neutral	C$18.85M	-5.08	-68.32%	―	2.41%	74.61%
RAMM	45 Neutral	C$2.39M	-1.18	-82.37%	―	-15.51%	-49.26%
PCLO	45 Neutral	C$6.92M	5.19	―	―	15.64%	58.47%